Revenue: As of FY2025 Q3, the actual value is USD 10 M.EPS: As of FY2025 Q3, the actual value is USD -8.07.EBIT: As of FY2025 Q3, the actual value is USD -14.18 M.<h3>Segment Revenue</h3><ul><li>License Revenue: For the nine months ended September 30, 2025, Evommune, Inc. recognized $13.0 million in license revenue, compared to $7.0 million for the same period in 2024. The increase was due to higher license revenue recognized under the Maruho Japan Agreement in 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Research and Development Expenses: $53.6 million for the nine months ended September 30, 2025, compared to $46.4 million for the same period in 2024. The increase was primarily due to increased clinical trial expenses for EVO756 and additional preclinical research expenses.</li><li>General and Administrative Expenses: $10.7 million for the nine months ended September 30, 2025, compared to $9.1 million for the same period in 2024. The increase was primarily due to increased personnel costs.</li><li>Net Loss: $40.6 million for the nine months ended September 30, 2025, compared to $46.1 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $59.7 million for the nine months ended September 30, 2025, compared to - $39.7 million for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $7.6 million for the nine months ended September 30, 2025, compared to $29.1 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $63.9 million for the nine months ended September 30, 2025, compared to - $0.3 million for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Evommune, Inc. plans to continue the research and development of its clinical- and preclinical-stage product candidates, including EVO756 and EVO301, and expects to incur significant expenses as it seeks regulatory approvals and expands its operational capabilities.</li><li>Non-Core Business: The company has entered into strategic collaborations, such as with Maruho Co., Ltd., to develop and commercialize its product candidates in specific regions, which may provide additional revenue streams and market opportunities.</li></ul>

Evommune | 10-Q: FY2025 Q3 Revenue: USD 10 M